The study provides insight into VC transactions that have taken place across all sectors and all regions across the globe and compares it with the North American healthcare industry. Sectors and regions that have received the maximum number and value of transactions are highlighted. Outlooks for key regions are also presented. Some of the key factors that are expected to impact investments in the next 12 to 18 months, such as regulatory changes, have also been covered. An attractiveness index to measure the VC attractiveness to fund the healthcare industry across various healthcare segments has been computed in this study.
VC Investments in North American Healthcare
Since 2006, both the volume and the value of VC investments have decreased, but the decrease in value was considerably high. There is a clear trend showing the increase in low value deals and a good reduction in the number of high value deals.
The early stage investments have decreased compared to late-stage funding.
A majority of the deals were made on the West Coast, including in Alaska, California, Hawaii, Oregon, and Washington.
Healthcare equipment, biotechnology, and pharmaceuticals are the leading segments that received investments both in terms of value and volume between 2006 and 2011.
With the doors of IPO almost shut for the venture capital investors, they are now looking at new routes for exits.
With the increase of strategic investments and corporate venturing in the pharmaceuticals and biotechnology segments, mergers and acquisitions and strategic buyouts have become attractive exit options.
Venture Capital Investment Attractiveness Index
The index compares the segment-wise attractiveness for venture capital investments in the North American healthcare industry.
Electronic Access - Single User Fulfilled By Publisher
Electronic Access - Global Site License Fulfilled By Publisher